A multicenter, randomised, double-blind, placebo-controlled, multiple-dose trial with rFXIII administered to subjects with mild to moderate active ulcerative colitis

Trial Profile

A multicenter, randomised, double-blind, placebo-controlled, multiple-dose trial with rFXIII administered to subjects with mild to moderate active ulcerative colitis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2014

At a glance

  • Drugs Catridecacog (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 01 Jun 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 03 Apr 2013 Planned End Date changed from 1 Feb 2014 to 1 Jan 2014, as reported by ClinicalTrials.gov.
    • 01 Mar 2013 Planned End Date changed from 1 Jan 2014 to 1 Feb 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top